(20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2

• Published in: International journal of molecular sciences Vol. 22; no. 17; p. 9289
• Main Authors: Wang, Yu-Shi, Chen, Chen, Zhang, Shi-Yin, Li, Yang, Jin, Ying-Hua
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2021; MDPI
• Subjects: (20S)G-Rh2; Angiogenesis; Annexin A2; Cancer; Cell activation; Cell culture; Cell cycle; Cell division; Cell growth; Cytokines; Gene expression; Kinases; Medical prognosis; Metastasis; Mutation; Phosphorylation; Protein-tyrosine kinase; Proteins; Signal processing; STAT3; Stat3 protein; Transcription activation; Transcription factors; Transducers; Tumor cells; Tumors; Tyrosine; Vascular endothelial growth factor; VEGF
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22179289

Signal transducers and activators of transcription 3 (STAT3) acts as a transcriptional signal transducer, converting cytokine stimulation into specific gene expression. In tumor cells, aberrant activation of the tyrosine kinase pathway leads to excessive and continuous activation of STAT3, which provides further signals for tumor cell growth and surrounding angiogenesis. In this process, the tumor-associated protein Annexin A2 interacts with STAT3 and promotes Tyr705 phosphorylation and STAT3 transcriptional activation. In this study, we found that (20S) ginsenoside Rh2 (G-Rh2), a natural compound inhibitor of Annexin A2, inhibited STAT3 activity in HepG2 cells. (20S) G-Rh2 interfered with the interaction between Annexin A2 and STAT3, and inhibited Tyr705 phosphorylation and subsequent transcriptional activity. The inhibitory activity of STAT3 leaded to the negative regulation of the four VEGFs, which significantly reduced the enhanced growth and migration ability of HUVECs in co-culture system. In addition, (20S)G-Rh2 failed to inhibit STAT3 activity in cells overexpressing (20S)G-Rh2 binding-deficient Annexin A2-K301A mutant, further proving Annexin A2-mediated inhibition of STAT3 by (20S)G-Rh2. These results indicate that (20S)G-Rh2 is a potent inhibitor of STAT3, predicting the potential activity of (20S)G-Rh2 in targeted therapy applications.